Resource Summary Report

Generated by RRID on May 23, 2025

Hep-G2/C3A

RRID:CVCL_1098
Type: Cell Line

Proper Citation

(RRID:CVCL_1098)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1098

Proper Citation: (RRID:CVCL_1098)

Sex: Male

Defining Citation: PMID:12068308, PMID:20164919, PMID:20215515, PMID:22460905, PMID:25485619, PMID:25877200, PMID:26589293, PMID:27397505, PMID:29468137, PMID:30894373, PMID:31068700, PMID:35839778

Comments: Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep exome analysis., Virology: Susceptible to infection by Zika virus (ZIKV) (PubMed=29468137)., Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Patented cell line.

Category: Cancer cell line

Name: Hep-G2/C3A

Synonyms: HepG2/C3A, Hep G2/C3A, C3A

Cross References: BTO:BTO_0003586, CLO:CLO_0002119, EFO:EFO_0002121, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-3610, ATCC:CRL-3581, ATCC:CRL-10741, BCRC:60177, BCRJ:0291, BioSample:SAMN03473207, BioSample:SAMN10987645, cancercelllines:CVCL_1098, Cell_Model_Passport:SIDM01237, ChEMBL-Cells:CHEMBL3308377, ChEMBL-Targets:CHEMBL1075402, Cosmic:724820, Cosmic:910850, Cosmic:1995354, Cosmic-CLP:910850, DepMap:ACH-001021,

EGA:EGAS00001000610, EGA:EGAS00001000978, FCS-free:10-2-11-3-4-4, GDSC:910850, GEO:GSM886899, GEO:GSM887964, GEO:GSM1669638, IARC_TP53:21205, IARC_TP53:27688, IGRhCellID:C3A, LINCS_LDP:LCL-1927, PharmacoDB:C3A_156_2019, PRIDE:PXD030304, Progenetix:CVCL_1098, PubChem_Cell_line:CVCL_1098, Ubigene:YC-C093, Wikidata:Q54882789

ID: CVCL_1098

Record Creation Time: 20250131T200406+0000

Record Last Update: 20250131T201627+0000

Ratings and Alerts

No rating or validation information has been found for Hep-G2/C3A.

No alerts have been found for Hep-G2/C3A.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 119 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID.

Bugide S, et al. (2024) ALK inhibitors suppress HCC and synergize with anti-PD-1 therapy and ABT-263 in preclinical models. iScience, 27(5), 109800.

Chen N, et al. (2023) Biocompatibility of the oxygen carrier polymerized human hemoglobin towards HepG2/C3A cells. Heliyon, 9(5), e15878.

N H, et al. (2023) In Vitro Hepatic Models to Assess Herb-Drug Interactions: Approaches and Challenges. Pharmaceuticals (Basel, Switzerland), 16(3).

Primadharsini PP, et al. (2023) Development and Characterization of Efficient Cell Culture Systems for Genotype 1 Hepatitis E Virus and Its Infectious cDNA Clone. Viruses, 15(4).

Nyambo K, et al. (2023) In-silico and in-vitro assessments of some fabaceae, rhamnaceae, apocynaceae, and anacardiaceae species against Mycobacterium tuberculosis H37Rv and triple-negative breast cancer cells. BMC complementary medicine and therapies, 23(1), 219.

Subramanian C, et al. (2023) Relief of CoA sequestration and restoration of mitochondrial function in a mouse model of propionic acidemia. Journal of inherited metabolic disease, 46(1), 28.

Schrader JA, et al. (2023) EGF receptor modulates HEV entry in human hepatocytes. Hepatology (Baltimore, Md.), 77(6), 2104.

Lin S, et al. (2023) Hepatitis E Virus: Isolation, Propagation, and Quantification. Current protocols, 3(1), e642.

Hsieh YY, et al. (2023) Repositioning VU-0365114 as a novel microtubule-destabilizing agent for treating cancer and overcoming drug resistance. Molecular oncology.

Meister TL, et al. (2022) A ribavirin-induced ORF2 single-nucleotide variant produces defective hepatitis E virus particles with immune decoy function. Proceedings of the National Academy of Sciences of the United States of America, 119(34), e2202653119.

Frandsen HS, et al. (2022) Mapping Proteome and Lipidome Changes in Early-Onset Non-Alcoholic Fatty Liver Disease Using Hepatic 3D Spheroids. Cells, 11(20).

Wang M, et al. (2022) Molecularly cleavable bioinks facilitate high-performance digital light processing-based bioprinting of functional volumetric soft tissues. Nature communications, 13(1), 3317.

Hernandez A, et al. (2022) Dihydroxyacetone suppresses mTOR nutrient signaling and induces mitochondrial stress in liver cells. PloS one, 17(12), e0278516.

Gabuza KB, et al. (2022) In vitro and in vivo hepatotoxicity study of Afriplex™ GRT through an inflammatory response. Toxicology reports, 9, 1920.

Carabias P, et al. (2022) Galectin-1 confers resistance to doxorubicin in hepatocellular carcinoma cells through modulation of P-glycoprotein expression. Cell death & disease, 13(1), 79.

Li H, et al. (2022) CRISPR/Cas9 Screens Reveal that Hexokinase 2 Enhances Cancer Stemness and Tumorigenicity by Activating the ACSL4-Fatty Acid ?-Oxidation Pathway. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 9(21), e2105126.

Ma Z, et al. (2022) Chronic hepatitis E: Advancing research and patient care. Journal of hepatology, 77(4), 1109.

Burkard T, et al. (2022) Viral Interference of Hepatitis C and E Virus Replication in Novel Experimental Co-Infection Systems. Cells, 11(6).

Doß S, et al. (2022) Influence of Antibiotics on Functionality and Viability of Liver Cells In Vitro. Current issues in molecular biology, 44(10), 4639.

Di Cristo L, et al. (2022) Grouping of orally ingested silica nanomaterials via use of an integrated approach to testing and assessment to streamline risk assessment. Particle and

fibre toxicology, 19(1), 68.